DJIA 17,117.09 85.95 0.50%
NASDAQ 4,535.03 16.13 0.36%
S&P 500 1,996.09 11.96 0.60%
market minute promo

Ophthotec (NASDAQ: OPHT)

39.04 0.34 (0.87%)

Quote as of

company name or ticker

Recent Quotes

OPHT $39.04 0.87%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $38.69
Previous Close $38.70
Daily Range $38.50 - $39.19
52-Week Range $22.61 - $47.99
Market Cap $1.3B
P/E Ratio 10.10
Dividend (Yield) $0.00 (0.0%)
Volume 94,159
Average Daily Volume 185,800
Current FY EPS -$3.43



Ophthotec (OPHT) Description

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration. Website:

News & Commentary

3 Future Biotechnology Blockbusters?

Medivation, Ophthotech, and Portola all have potential blockbusters on their hands.

Sector Update: Health-Care Shares Mixed in Pre-Market Trade

Sector Update: Health Care

Ophthotech's (OPHT) CEO David Guyer on Q2 2014 Results - Earnings Call Transcript

Benzinga's Top Initiations

Roundtable: 3 Stocks Janet Yellen Is Dead Wrong About

The Fed thinks biotech stocks are overvalued. Here's where they're wrong.

Is Opthotech Your Next Multibagger Stock?

Opthotech is working on a treatment for wet AMD that could have sales potential equal to that of Novartis' Lucentis or Regeneron's (REGN) Eylea.

Ohr Pharmaceutical: Questionable Analyst Activity

Phase II Calamity Dooms Ohr's Eye Drops

3 Stocks Near 52-Week Highs Worth Selling

Are these three stocks sells or belles? You be the judge!

See More OPHT News...